Business
Heidelberg Pharma to Present at the Life Sciences Virtual Investor Forum June 12th
Heidelberg Pharma invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.comLADENBURG, Germany, June 06, 2025 (GLOBE NEWSWIRE) -- Heidelberg Pharma AG (XETRA: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that Andreas Pahl, CEO of Heidelberg Pharma, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on June
About this update from Heidelberg Pharma Ag
[{"type":"image","alt":"Virtual Investor Conferences","displaySize":"","headline":null,"caption":"Virtual Investor Conferences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/7e30d4a58a8d048d2ee1986670b581bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wFNFO9V7weOyJzKv3Grwwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7e30d4a58a8d048d2ee1986670b581bc","width":300,"height":200}},"lazy":false},{"type":"text","content":"Heidelberg Pharma invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com","length":150,"tagName":"p"},{"type":"text","content":"LADENBURG, Germany, June 06, 2025 (GLOBE NEWSWIRE) -- Heidelberg Pharma AG (XETRA: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that Andreas Pahl, CEO of Heidelberg Pharma, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on June 12th, 2025.","length":362,"tagName":"p"},{"type":"text","content":"Heidelberg Pharma’s lead candidate, HDP-101, a BCMA-targeting ADC with the novel payload Amanitin, is being evaluated in a Phase I/IIa clinical trial for the treatment of relapsed or refractory Multiple Myeloma. HDP-101 is showing promising results, including a prolonged complete response in a patient who had undergone extensive prior treatment. The patient has received continuous treatment with HDP-101 alone for over 19 months, showing excellent tolerability of the drug.","length":476,"tagName":"p"},{"type":"text","content":"In addition, promising biological activity and objective improvements were observed in several patients, underscoring the potential of HDP-101 as a treatment option for Multiple Myeloma. Dose escalation is continuing, and the study is advancing in cohort 8.","length":257,"tagName":"p"},{"type":"text","content":"Furthermore, the second candidate, HDP-102, a CD-37-targeting ADC with the novel payload Amanitin, has recently entered clinical development and the first patient has been dosed in a Phase I study for the treatment of non-Hodgkin lymphoma (NHL).","length":245,"tagName":"p"},{"type":"text","content":"DATE: June 12th TIME: 10:00 AM ETLINK: REGISTER HERE...